BlinkLab (ASX: BB1) Launches Nationwide Autism Screening Program in Morocco's Tangier, Fes and Agadir

Aditi Sarkar

22 October 2026 06:44 PM AEDT

BlinkLab (ASX: BB1) Launches Nationwide Autism Screening Program in Morocco's Tangier, Fes and Agadir

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Morocco’s nationwide, government-funded autism screening program has commenced in Tangier, Fes and Agadir.
It is the first operational rollout under the national framework announced on 23 March 2026.
BlinkLab staff travelled to Morocco to train local healthcare professionals as the first centres begin integrating the program into clinical workflows.
Morocco has about 600,000 children born annually, and the program may support phased expansion across the country.

BlinkLab Limited (ASX:BB1) has announced the commencement of the nationwide Autism Screening Program for the Kingdom of Morocco in the cities of Tangier, Fes and Agadir. The launch is the first operational phase of the government-funded initiative that BlinkLab was selected for in March 2026, and it moves the program from policy design into clinical practice.

Program Launch and National Framework

The program was announced on 23 March 2026 and sits within a formal national framework involving the Foundation Mohammed V for Solidarity and the ministries responsible for higher education and research, health and social protection, and solidarity and social integration. The release says the program is being launched under the High Instructions of His Majesty King Mohammed VI.

The initial commencement in Tangier marks the transition to implementation across a nationwide healthcare system serving about 600,000 children born each year across a large geographical footprint.

On-the-Ground Training

BlinkLab staff travelled to Tangier to train local healthcare professionals and support initial implementation, preparing the first operational teams to use the company’s smartphone-based autism screening technology within the Moroccan clinical pathway.

Managing Director and CEO Dr Henk-Jan Boele said the team is proud to see the program enter its first operational phase across three major cities, and noted that the team also visited Morocco in June to meet staff overseeing the rollout.

Strategic Significance

Dr Mohamed Azami, Coordinator and Administrator of the Mohammed V Foundation for Solidarity, said the program aims to build a modern and equitable system of early identification, care and support, with a model that can be scaled across the Kingdom and potentially inform collaboration across North Africa, the Gulf and the wider Middle East.

BlinkLab says the launch gives it its first live implementation reference point for a government-led screening program and may support phased expansion across Morocco. The announcement does not state financial terms or revenue expectations. BlinkLab Dx1, its most advanced product, is an autism diagnostic aid for clinicians using smartphones, AI and machine learning to capture objective, reflex-based measures.

Key Takeaways

BlinkLab’s technology is now being introduced in a live, government-led screening program in three Moroccan cities. The release is about implementation milestones and does not disclose revenue or screening volumes, so further updates on expansion and results will be the key things to watch. This article is general information only and is not financial advice.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.